Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06GRK
|
|||
| Former ID |
DNCL001956
|
|||
| Drug Name |
ARC029
|
|||
| Synonyms |
Nilvadipine; nilvadipine; 75530-68-6; Escor; Nivadil; Nivadipine; FR-34235; Nilvadipinum [Latin]; Nilvadipino [Spanish]; FR 34235; FK 235; Nilvadipine [USAN:INN:JAN]; Nilvadipine (ARC029); FK-235; F-102362; BRN 3572609; F 102,362; CL-287389; CL 287,389; FAIIFDPAEUKBEP-UHFFFAOYSA-N; C19H19N3O6; NCGC00167435-01; 5-Isopropyl 3-methyl 2-cyano-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 3,5-Pyridinedicarboxylic acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) ester; Nilvadipino; NILVADIPINE
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 3 | [1] | |
| Company |
Archer Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H19N3O6
|
|||
| Canonical SMILES |
CC1=C(C(C(=C(N1)C#N)C(=O)OC)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC(C)C
|
|||
| InChI |
1S/C19H19N3O6/c1-10(2)28-19(24)15-11(3)21-14(9-20)17(18(23)27-4)16(15)12-6-5-7-13(8-12)22(25)26/h5-8,10,16,21H,1-4H3
|
|||
| InChIKey |
FAIIFDPAEUKBEP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 75530-68-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7404098, 7848970, 8152767, 12013601, 14829624, 29223588, 50032142, 50112689, 57322296, 76419116, 91615151, 99443264, 103650265, 103825417, 104306568, 114918123, 117482643, 117550807, 118844956, 124893312, 125357242, 126684563, 131325620, 134224176, 134349141, 135011626, 135692559, 135727167, 137173173, 142970901, 144205992, 152046996, 160810045, 160846951, 160967881, 162178897, 163088366, 164814634, 175611951, 179148723, 184546033, 185987117, 187072433, 206245192, 210275074, 210280712, 223401140, 223680726, 223702474, 224966744
|
|||
| ChEBI ID |
CHEBI:31911
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031727) | |||
| REF 2 | Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J Med Chem. 1989 Oct;32(10):2399-406. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.